ABBVAbbVieSigning up patients
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 180 (planned)
- Started
- Nov 25, 2025
- Main results expected
- Apr 2029
- Fully finished
- Sep 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AE)s
Measured over: Up to 69.5 Months
Progression-Free Survival (PFS) Based on Investigator Assessment
Measured over: Up to Approximately 24 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07155174 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC